GlobeNewswire Inc.··NaMonopar Therapeutics Reports $137.5M Cash, Advances Wilson Disease Treatment
Monopar reports Q1 2026 results with $137.5M cash, $3.9M net loss. ALXN1840 shows superior efficacy in Phase 3 trial; FDA submission planned mid-2026.
MNPRFDA approvalNDA submission